LU90234I2 - Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine - Google Patents

Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine

Info

Publication number
LU90234I2
LU90234I2 LU90234C LU90234C LU90234I2 LU 90234 I2 LU90234 I2 LU 90234I2 LU 90234 C LU90234 C LU 90234C LU 90234 C LU90234 C LU 90234C LU 90234 I2 LU90234 I2 LU 90234I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
lamivudine
zidovudine
optionally
combination
Prior art date
Application number
LU90234C
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90234(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919110624A external-priority patent/GB9110624D0/en
Priority claimed from GB919121381A external-priority patent/GB9121381D0/en
Priority claimed from GB919123581A external-priority patent/GB9123581D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of LU90234I2 publication Critical patent/LU90234I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU90234C 1991-05-16 1998-04-24 Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine LU90234I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919110624A GB9110624D0 (en) 1991-05-16 1991-05-16 Combinations
GB919121381A GB9121381D0 (en) 1991-10-08 1991-10-08 Combinations
GB919123581A GB9123581D0 (en) 1991-11-06 1991-11-06 Combinations

Publications (1)

Publication Number Publication Date
LU90234I2 true LU90234I2 (fr) 1998-06-24

Family

ID=27265656

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90234C LU90234I2 (fr) 1991-05-16 1998-04-24 Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine

Country Status (25)

Country Link
US (2) US5627186A (fr)
EP (1) EP0513917B2 (fr)
JP (1) JP2868671B2 (fr)
KR (1) KR100246687B1 (fr)
CN (1) CN1045961C (fr)
AT (1) ATE131730T1 (fr)
AU (2) AU1787492A (fr)
CA (1) CA2068790C (fr)
CZ (1) CZ285232B6 (fr)
DE (2) DE19875016I2 (fr)
DK (1) DK0513917T4 (fr)
ES (1) ES2083668T5 (fr)
GR (1) GR3018915T3 (fr)
HK (1) HK78897A (fr)
IE (1) IE73261B1 (fr)
IL (1) IL101883A (fr)
LU (1) LU90234I2 (fr)
MX (1) MX9202279A (fr)
NL (1) NL980018I2 (fr)
NO (2) NO301690B1 (fr)
NZ (2) NZ299240A (fr)
OA (1) OA10058A (fr)
SK (1) SK279262B6 (fr)
TW (1) TW273550B (fr)
WO (1) WO1992020344A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
BR9709939A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
DE69840216D1 (de) 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
EP1200130A2 (fr) 1999-07-22 2002-05-02 Newbiotics, Inc. Procedes pour traiter les tumeurs resistantes aux therapies
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
WO2004043433A2 (fr) * 2002-11-08 2004-05-27 Glaxo Group Limited Preparations pharmaceutiques
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
US7662852B2 (en) 2003-05-22 2010-02-16 Lead Chemical Co., Ltd. Compounds and preparations having antiviral effect
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1975923B1 (fr) * 2007-03-28 2016-04-27 Nuance Communications, Inc. Reconnaissance vocale non-native plurilingues
EP2435052B1 (fr) 2009-05-27 2015-07-15 Hetero Research Foundation Formes pharmaceutiques solides de lamivudine s'administrant par voie orale avec isomalt
EP2579892A2 (fr) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
US20150104511A1 (en) 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
GB8717955D0 (en) * 1987-07-29 1987-09-03 Fujisawa Pharmaceutical Co Prevention & treatment of aids
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
WO1989009056A1 (fr) * 1988-03-23 1989-10-05 New York University Composition antivirale contenant des diones aromatiques polycycliques et des analogues de nucleosides, et procede de traitement d'infections retrovirales
JPH02504283A (ja) * 1988-03-23 1990-12-06 ニューヨーク　ユニバーシィティ 芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
EP0362162B1 (fr) * 1988-09-28 1992-03-04 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Composition pharmaceutique comprenant de la zinovudine et de l'inosiplex ou leurs composants pour le traitement du SIDA ou de syndromes apparentés au SIDA
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv History of tetrahydroimidazo [1,4] benzodiazepine-2-thione, their preparation and pharmaceutical preparations containing them
GR1000618B (el) * 1989-03-17 1992-08-31 Oncogen Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) † 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
EP0513917A1 (fr) 1992-11-19
CZ285232B6 (cs) 1999-06-16
KR100246687B1 (ko) 2000-04-01
JP2868671B2 (ja) 1999-03-10
DE69206876T3 (de) 2004-08-12
NO1999018I1 (no) 1999-07-22
NL980018I1 (nl) 1998-07-01
KR920021148A (ko) 1992-12-18
US5859021A (en) 1999-01-12
CZ242893A3 (en) 1994-07-13
OA10058A (en) 1996-10-14
DK0513917T3 (da) 1996-02-05
IE73261B1 (en) 1997-05-21
TW273550B (fr) 1996-04-01
NO921947L (no) 1992-11-17
NO301690B1 (no) 1997-12-01
AU1787492A (en) 1992-12-30
AU661307B2 (en) 1995-07-20
IE921566A1 (en) 1992-11-18
SK119993A3 (en) 1994-04-06
DK0513917T4 (da) 2001-06-25
NZ299240A (en) 2004-11-26
CN1068570A (zh) 1993-02-03
ATE131730T1 (de) 1996-01-15
NL980018I2 (nl) 1998-11-02
WO1992020344A1 (fr) 1992-11-26
DE69206876T2 (de) 1996-05-23
IL101883A0 (en) 1992-12-30
DE69206876D1 (de) 1996-02-01
EP0513917B1 (fr) 1995-12-20
CA2068790C (fr) 2005-06-07
SK279262B6 (sk) 1998-08-05
DE19875016I2 (de) 2004-07-01
NZ242754A (en) 1996-11-26
CA2068790A1 (fr) 1992-11-17
JPH06234641A (ja) 1994-08-23
MX9202279A (es) 1992-11-01
GR3018915T3 (en) 1996-05-31
NO921947D0 (no) 1992-05-15
US5627186A (en) 1997-05-06
ES2083668T3 (es) 1996-04-16
IL101883A (en) 1998-10-30
ES2083668T5 (es) 2001-06-16
CN1045961C (zh) 1999-10-27
HK78897A (en) 1997-06-20
EP0513917B2 (fr) 2001-03-07
AU1627992A (en) 1992-11-19

Similar Documents

Publication Publication Date Title
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
DK0539204T3 (da) Antivirale 4-substituerede-deoxy-2,3-didehydroderivater af alfa-D-neuraminsyre
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
MX172953B (es) Derivados de 2-aminopirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
EP0388049A3 (fr) Dérivés de penciclovir pour le traitement d'infections de l'Hépatite-B
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
ES2078380T3 (es) Oligofosfatos de accion antiviral.
EP0509098A4 (en) Ataractic
KR960021045A (ko) 페루릭산을 포함하는 b형 간염 치료제
IT8719351A0 (it) Composti ad attivita'epatoprotettrice e mucolitica, procedimento per la loro preparazione e composizioni farmaceutiche relative.
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제